# OnCo record aldesleukin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/aldesleukin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "aldesleukin" ;
  schema:name "Aldesleukin (high-dose IL-2)"@en ;
  schema:alternateName "Interleukin-2"@en, "IL-2"@en, "Recombinant interleukin-2"@en, "Proleukin" ;
  schema:description "High-dose interleukin-2 was the first immunotherapy to cure a small fraction of patients with metastatic melanoma and kidney cancer, at the cost of ICU-level toxicity; today it mainly supports TIL therapy."@en ;
  schema:url <https://onco.cc/drugs/aldesleukin/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Aldesleukin> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=aldesleukin> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "historic" ;
  onco:modality "Recombinant interleukin-2 (cytokine)" ;
  onco:approval "US 1992: Metastatic renal cell carcinoma", "US 1998: Metastatic melanoma" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/til-therapy/> ;
  onco:companies <https://onco.cc/companies/iovance/> ;
  onco:trials <https://onco.cc/trials/nct06119685/>, <https://onco.cc/trials/nct07681596/> .